LaunchPad Medical says that it has successfully enrolled half of the 20 patients approved by the US Food and Drug Administration (FDA) for its two-site pilot
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas will collaborate on a randomized clinical trial comparing the outcomes and side effects